EP2151494A2 - Maltogenic alpha-amylase variants - Google Patents
Maltogenic alpha-amylase variants Download PDFInfo
- Publication number
- EP2151494A2 EP2151494A2 EP09173277A EP09173277A EP2151494A2 EP 2151494 A2 EP2151494 A2 EP 2151494A2 EP 09173277 A EP09173277 A EP 09173277A EP 09173277 A EP09173277 A EP 09173277A EP 2151494 A2 EP2151494 A2 EP 2151494A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- maltose
- polypeptide
- glucose
- seq
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01133—Glucan 1,4-alpha-maltohydrolase (3.2.1.133), i.e. maltogenic alpha-amylase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the invention relates to the preparation of variants of a parent maltogenic alpha-amylase, where hydrolysis products of said variants having a modified of maltose-to-glucose ratio as compared to hydrolysis products of the parent maltogenic alpha-amylase. It also relates to a polynucleotide encoding such variants and to the use of the variants in the production of ethanol, beer, dough, maltose syrup and baked products.
- Maltogenic alpha-amylase (EC 3.2.1.1) is known to be useful, e.g., for production of ethanol from granular starch by fermentation ( WO 2003068976 ) and for retarding the staling of bread ( WO 9104669 ).
- One maltogenic alpha-amylase is the commercial product Novamyl ® described in EP 120693 B1 .
- Variants of Novamyl are known from WO 9943794 .
- Maltogenic alpha-amylases are known to hydrolyze starch with formation of maltose as the main product together with a minor amount glucose.
- the inventors realized that in some applications the control of the maltose-to-glucose ratio is of great importance. Particularly for ethanol production from granular starch by fermentation, it may be an advantage to form a larger amount of glucose which is more readily fermentable than maltose. Particularly for production of maltose syrups glucose is an undesired product, and hence it of interest to increase the maltose-to-glucose ratio. They then developed a method of constructing such variants of based on the three-dimensional structure of a parent maltogenic alpha-amylase.
- the invention provides a method of constructing a variant polypeptide, comprising:
- the parent maltogenic alpha-amylase and the substrate may for the purpose of steps a), b), and c) be provided in the form of a computer model.
- the invention also provides a variant polypeptide which
- the invention provides a polynucleotide encoding the polypeptide and uses of the polypeptide in production of ethanol from granular starch by fermentation, in production of maltose syrup, and in the production of dough and baked products.
- the maltogenic alpha-amylase (EC 3.2.1.133) may have the amino acid sequence shown in SEQ ID NO: 1 (in the following referred to as Novamyl) with a 3D structure including a substrate as described in US 6162628 and found in the Protein Data Bank with the identifier 1QHO.
- the maltogenic alpha-amylase may be a Novamyl variant described in US 6162628 .
- a 3D structure of such a variant may be developed from the Novamyl structure by known methods, e.g. as described in T.L. Blundell et al., Nature, vol. 326, p. 347 ff (26 March 1987 ); J. Greer, Proteins: Structure, Function and Genetics, 7:317-334 (1990 ); or Example 1 of WO 9623874 .
- An amino acid residue is selected which has a C-alpha atom located ⁇ 10 ⁇ from an atom of the substrate.
- the following residues are selected by this criterion: 13, 15, 18, 43-44, 70, 72-73, 77-78, 82, 86-94, 97, 127-136, 143, 174-180, 183-184, 187-198, 226-233, 255-267, 270, 282-289, 291-292, 299, 307, 324, 327-331, 360, 370-376.
- the selection may in particular be for residues ⁇ 10 ⁇ from an atom in monosaccharide (glucose) moieties +1, +2 and +3 at the reducing side of the cleavage point.
- the moieties are denoted j, k and I, and this lead to selection of the following residues: 13, 70, 73, 90, 92-93, 127-132, 174-180, 183-184, 187-191, 196, 226-233, 255-267, 270, 282-289, 291-292, 299, 307, 324, 327-331, 371-372, 375-376.
- the selected residue may be substituted so as to push the substrate away or block for it presents in position +1, +2 and +3 etc by making the residues larger at a position corresponding to G172, D178, T189, K231, H232, Y258, G259, D260, T264, N266 or T288 in Novamyl (SEQ ID NO: 1), e.g. a substitution corresponding to G172V, T189M, K231R, H232Y, Y258W, G259A/H/Y, T264Y/Q/F, N266Y or T288Y/Q/F/P.
- substitution may serve to remove hydrogen bonding or van der Waals contact to the substrate at position +1, +2 and +3. This may be done by substituting with a smaller residue at a position corresponding to W93, T134, D178, D190, D198, 1227, K231, H232, F233, Y258, D260, D261, T264 or T288 of SEQ ID NO: 1, particularly a substitution corresponding to W93S/G/V/T/M/E, T134A, D178L/M/T/V, D190G, D198G, I227V, K231L/M, H232L/M, F233S, Y258L/M/T/V, D260L/M/T/V, D261 G, T264A/V or T288A/V.
- a hydrophilic or electrically charged (positive or negative) residue may be substituted with a hydrophobic residue, particularly at a position corresponding to T134, D178, D190, D198, K231, H232 or D261, more particularly a substitution corresponding to T134A, D178V, D190G, D198G, K231L/M, H232L/M or D261G.
- substitution or deletion may serve to change indirectly the contact by changing the residues next to the substrate contact residues, particularly a residue corresponding to W93, N176, 191, 192, 193, 194,195, V230, P262, F284 or M330 in Novamyl, e.g. a substitution corresponding to W93E/G/M/V/T/S, N176L, V230G, F284Y or M330I or a deletion of residues corresponding to 191, 192, 193, 194, and 195.
- amino acid residues are considered to be hydrophobic: G, A, V, L, I, P, F, W and C as part of a disulfide bridge.
- Some particular variants according to the invention have the sequence of SEQ ID NO: 1 with the following substitutions: W93M W93E W93M, V230G Y258W Y258W, F284Y H232M F188T F188G F188V W93G W93V W93T W93S N176L D178V F188G, W93M F188G, W93E F188G, W93S F188G, W93T F188V, W93M F188V, W93E F188V, W93S F188V, W93T
- the variant of the invention is able to hydrolyze starch to form a product having a modified maltose-to-glucose ratio as compared to a product made with the polypeptide of SEQ ID NO: 1.
- the starch hydrolysis may be carried out by the following procedures described in the examples.
- the variants of the invention may show an increased ratio of glucose to maltose (DP1/DP2) or an increased ratio of DP1/(DP1-4) or an increased ratio of maltose to glucose (DP2/DP1) or an increased ratio of (DP1-4)/DP1.
- Starch is in the context of the present invention intended to include starch as well as breakdown products of starch, such as amylopectin, or amylose, or maltooligosaccharides.
- the polypeptide of the invention may have identities to the disclosed sequences of at least 80 %, particularly at least 85 % or at least 90 %, e.g. at least 91%, or 92%, or 93%, or 94%, or at least 95 %, such as 96%, or 97%, or 98%, or 99%.
- alignments of sequences and calculation of identity scores may be done using a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments.
- the default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively.
- the penalty for the first residue in a gap is -12 for proteins and -16 for DNA, while the penalty for additional residues in a gap is -2 for proteins and -4 for DNA.
- Alignment is from the FASTA package version v20u6 ( W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448 , and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183:63-98 ).
- the variant of the invention may be used in various known applications for amylases, e.g. production of ethanol, beer, dough, maltose syrup and baked products.
- the variant may be used in a process comprising treating granular starch with the variant and fermentation into ethanol.
- the treatment of the granular starch serves to produce a hydrolysis product which includes a significant amount of glucose.
- the fermentation to produce ethanol may be simultaneous with the granular starch treatment, or the starch may first be hydrolyzed followed by fermentation of the hydrolysate.
- the process may be performed as described in WO 2003068976 .
- the variant may be used in mashing, i.e. in the process of converting starch from milled malt and solid adjuncts into fermentable and unfermentable sugars to produce wort.
- mashing involves incubating the variant with milled malt and solid adjuncts in water to hydrolyze the starch.
- the variant may be added to dough for making baked products such as bread. Addition of the variant may serve to retard staling of the baked product.
- the addition to dough may be done as described in WO 9104669 .
- the variant may be used for commercial production of maltose, which today starts from liquefied starch (DE ⁇ 10), which is subsequently treated simultaneously with debranching enzymes (pullulanase or isoamylase) and maltose-forming enzymes (maltogenic ⁇ -amylase or ⁇ -amylase) at a temperature around 60°C.
- debranching enzymes pulseulanase or isoamylase
- maltose-forming enzymes maltogenic ⁇ -amylase or ⁇ -amylase
- Maltose is used in large quantities as syrups in e.g. the confectionary industry and as a sweetening agent in the food industry.
- Maltose syrups have among other capacities reduced browning capacity, a resistance to moisture absorption and to crystallization making maltose syrups suited for e.g. frozen dessert formulations, hard candy, jams, and jellies.
- a maltogenic alpha-amylase with an increased maltose-to-glucose ratio would be an advantage in the production of maltose syrups.
- the carbohydrate profile was determined by chromatography by applying standard procedures, e.g. as described in Norman,B.E. in James N.Bemiller, David J.Manners, and Robert J.Sturgeon (eds), Methods in Carbohydrate Chemistry, Volume X. John Wiley & Sons, Inc., New York, pp. 231-239, 1994 . Novamyl without substitutions was included as reference.
- a number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase” in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000 .
- Each variant was tested by incubating it with maltodextrin (DE 11) at 60°C and pH 5.5 for 42 hours as described in Example 1. Either an amount of 0.81 micro g (variants marked with [1]) or 1.62 micro g (variants marked with [2]) of the variant was added, and further 1.2 mg/g DS of the commercially available pullulanase Promozyme® ( EP 63909 ) was added. Novamyl without substitutions was included as reference.
- a number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase” in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000 .
- a number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase” in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000 .
- amylopectin waxy maize starch
- the carbohydrate profile was determined by chromatography by applying standard procedures, e.g. as described in Norman,B.E. in James N.Bemiller, David J.Manners, and Robert J.Sturgeon (eds), Methods in Carbohydrate Chemistry, Volume X. John Wiley & Sons, Inc., New York, pp. 231-239, 1994 . Novamyl without substitutions was included as reference.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The invention relates to the preparation of variants of a parent maltogenic alpha-amylase, where hydrolysis products of said variants having a modified of maltose-to-glucose ratio as compared to hydrolysis products of the parent maltogenic alpha-amylase. It also relates to a polynucleotide encoding such variants and to the use of the variants in the production of ethanol, beer, dough, maltose syrup and baked products.
- Maltogenic alpha-amylase (EC 3.2.1.1) is known to be useful, e.g., for production of ethanol from granular starch by fermentation (
WO 2003068976 ) and for retarding the staling of bread (WO 9104669 EP 120693 B1 WO 9943794 - The inventors realized that in some applications the control of the maltose-to-glucose ratio is of great importance. Particularly for ethanol production from granular starch by fermentation, it may be an advantage to form a larger amount of glucose which is more readily fermentable than maltose. Particularly for production of maltose syrups glucose is an undesired product, and hence it of interest to increase the maltose-to-glucose ratio. They then developed a method of constructing such variants of based on the three-dimensional structure of a parent maltogenic alpha-amylase.
- Accordingly, the invention provides a method of constructing a variant polypeptide, comprising:
- a) providing a parent maltogenic alpha-amylase having an amino acid sequence and a three-dimensional structure which includes a cleavage point and a substrate with at least three monosaccharide moieties at the reducing side of the cleavage point,
- b) selecting an amino acid residue having a C-alpha atom located <10 Å from an atom in the substrate,
- c) substituting or deleting the selected residue to obtain a modified amino acid sequence,
- d) preparing a polypeptide having the modified sequence,
- e) testing the modified polypeptide by incubating it with starch and analyzing the reaction product, and
- f) selecting a modified polypeptide which has the ability to hydrolyze starch and wherein the hydrolysis product has a modified maltose-to-glucose ratio compared to an hydrolysis product made with the parent maltogenic alpha-amylase.
- The parent maltogenic alpha-amylase and the substrate may for the purpose of steps a), b), and c) be provided in the form of a computer model.
- The invention also provides a variant polypeptide which
- a) has an amino acid sequence having more than 80 % identity to SEQ ID NO: 1,
- b) compared to SEQ ID NO: 1 has a different amino acid residue at a position corresponding to W93, T134, G172, N176, D178, F188, D190, D198, 1227 V230, K231, H232, F233, Y258, G259, D260, D261, P262, T264, N266, F284, T288 or M330 or a deletion corresponding to 191-195, and
- c) has the ability to hydrolyze starch to form an product having a modified maltose-to-glucose ratio than a product made with the polypeptide of SEQ ID NO: 1.
- Finally, the invention provides a polynucleotide encoding the polypeptide and uses of the polypeptide in production of ethanol from granular starch by fermentation, in production of maltose syrup, and in the production of dough and baked products.
- The maltogenic alpha-amylase (EC 3.2.1.133) may have the amino acid sequence shown in SEQ ID NO: 1 (in the following referred to as Novamyl) with a 3D structure including a substrate as described in
US 6162628 and found in the Protein Data Bank with the identifier 1QHO. Alternatively, the maltogenic alpha-amylase may be a Novamyl variant described inUS 6162628 . A 3D structure of such a variant may be developed from the Novamyl structure by known methods, e.g. as described in T.L. Blundell et al., Nature, vol. 326, p. 347 ff (26 March 1987); J. Greer, Proteins: Structure, Function and Genetics, 7:317-334 (1990); or Example 1 ofWO 9623874 - An amino acid residue is selected which has a C-alpha atom located <10 Å from an atom of the substrate. In 1qho, the following residues are selected by this criterion: 13, 15, 18, 43-44, 70, 72-73, 77-78, 82, 86-94, 97, 127-136, 143, 174-180, 183-184, 187-198, 226-233, 255-267, 270, 282-289, 291-292, 299, 307, 324, 327-331, 360, 370-376.
- The selection may in particular be for residues <10 Å from an atom in monosaccharide (glucose) moieties +1, +2 and +3 at the reducing side of the cleavage point. In 1qho, the moieties are denoted j, k and I, and this lead to selection of the following residues: 13, 70, 73, 90, 92-93, 127-132, 174-180, 183-184, 187-191, 196, 226-233, 255-267, 270, 282-289, 291-292, 299, 307, 324, 327-331, 371-372, 375-376.
- The selected residue may be substituted so as to push the substrate away or block for it presents in position +1, +2 and +3 etc by making the residues larger at a position corresponding to G172, D178, T189, K231, H232, Y258, G259, D260, T264, N266 or T288 in Novamyl (SEQ ID NO: 1), e.g. a substitution corresponding to G172V, T189M, K231R, H232Y, Y258W, G259A/H/Y, T264Y/Q/F, N266Y or T288Y/Q/F/P.
- The substitution may serve to remove hydrogen bonding or van der Waals contact to the substrate at position +1, +2 and +3. This may be done by substituting with a smaller residue at a position corresponding to W93, T134, D178, D190, D198, 1227, K231, H232, F233, Y258, D260, D261, T264 or T288 of SEQ ID NO: 1, particularly a substitution corresponding to W93S/G/V/T/M/E, T134A, D178L/M/T/V, D190G, D198G, I227V, K231L/M, H232L/M, F233S, Y258L/M/T/V, D260L/M/T/V, D261 G, T264A/V or T288A/V.
- Alternatively, a hydrophilic or electrically charged (positive or negative) residue may be substituted with a hydrophobic residue, particularly at a position corresponding to T134, D178, D190, D198, K231, H232 or D261, more particularly a substitution corresponding to T134A, D178V, D190G, D198G, K231L/M, H232L/M or D261G.
- Finally, the substitution or deletion may serve to change indirectly the contact by changing the residues next to the substrate contact residues, particularly a residue corresponding to W93, N176, 191, 192, 193, 194,195, V230, P262, F284 or M330 in Novamyl, e.g. a substitution corresponding to W93E/G/M/V/T/S, N176L, V230G, F284Y or M330I or a deletion of residues corresponding to 191, 192, 193, 194, and 195.
-
- The following amino acid residues are considered to be hydrophobic: G, A, V, L, I, P, F, W and C as part of a disulfide bridge.
- Some particular variants according to the invention have the sequence of SEQ ID NO: 1 with the following substitutions:
W93M W93E W93M, V230G Y258W Y258W, F284Y H232M F188T F188G F188V W93G W93V W93T W93S N176L D178V F188G, W93M F188G, W93E F188G, W93S F188G, W93T F188V, W93M F188V, W93E F188V, W93S F188V, W93T - The variant of the invention is able to hydrolyze starch to form a product having a modified maltose-to-glucose ratio as compared to a product made with the polypeptide of SEQ ID NO: 1. The starch hydrolysis may be carried out by the following procedures described in the examples. The variants of the invention may show an increased ratio of glucose to maltose (DP1/DP2) or an increased ratio of DP1/(DP1-4) or an increased ratio of maltose to glucose (DP2/DP1) or an increased ratio of (DP1-4)/DP1.
- Starch is in the context of the present invention intended to include starch as well as breakdown products of starch, such as amylopectin, or amylose, or maltooligosaccharides.
- The polypeptide of the invention may have identities to the disclosed sequences of at least 80 %, particularly at least 85 % or at least 90 %, e.g. at least 91%, or 92%, or 93%, or 94%, or at least 95 %, such as 96%, or 97%, or 98%, or 99%.
- For purposes of the present invention, alignments of sequences and calculation of identity scores may be done using a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap is -12 for proteins and -16 for DNA, while the penalty for additional residues in a gap is -2 for proteins and -4 for DNA. Alignment is from the FASTA package version v20u6 (W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183:63-98).
- The variant of the invention may be used in various known applications for amylases, e.g. production of ethanol, beer, dough, maltose syrup and baked products.
- The variant may be used in a process comprising treating granular starch with the variant and fermentation into ethanol. The treatment of the granular starch serves to produce a hydrolysis product which includes a significant amount of glucose. The fermentation to produce ethanol may be simultaneous with the granular starch treatment, or the starch may first be hydrolyzed followed by fermentation of the hydrolysate. The process may be performed as described in
WO 2003068976 . - The variant may be used in mashing, i.e. in the process of converting starch from milled malt and solid adjuncts into fermentable and unfermentable sugars to produce wort. The mashing involves incubating the variant with milled malt and solid adjuncts in water to hydrolyze the starch.
- The variant may be added to dough for making baked products such as bread. Addition of the variant may serve to retard staling of the baked product. The addition to dough may be done as described in
WO 9104669 - The variant may be used for commercial production of maltose, which today starts from liquefied starch (DE<10), which is subsequently treated simultaneously with debranching enzymes (pullulanase or isoamylase) and maltose-forming enzymes (maltogenic α-amylase or β-amylase) at a temperature around 60°C. Glucose is an undesired side product in maltose syrups because it impacts the crystallization of maltose. Maltose is used in large quantities as syrups in e.g. the confectionary industry and as a sweetening agent in the food industry. Maltose syrups have among other capacities reduced browning capacity, a resistance to moisture absorption and to crystallization making maltose syrups suited for e.g. frozen dessert formulations, hard candy, jams, and jellies. Thus, a maltogenic alpha-amylase with an increased maltose-to-glucose ratio would be an advantage in the production of maltose syrups.
- A number of variants were prepared, each having the sequence of SEQ ID NO: 1 with the indicated substitutions. Each variant was tested by incubating it with maltodextrin (DE 11) by application of the following procedure:
- Prepare a 30% (w/w) maltodextrin solution (DE 11) in 50mM Na-acetate, 1mM CaCl2 pH 5.5. Is heated to 60°C for dissolving the maltodextrins.
- 1ml substrate is added to 1.5 ml tubes with lid and membrane, and samples are preheated to 60°C on a thermomixer.
- 1-100 microliter fermentation broth was added to 1ml preheated substrate. The fermentation broth volumes were adjusted thus, that they all contained the same amount of amylase activity measured by the Phadebas amylase assay.
- Samples are incubated for 42h at 60°C.
- Make a small hole in the lid with e.g. a needle.
- Samples are boiled for 15 minutes (or 99°C at the thermomixer).
- Add 1ml Milli-Q.
- After cooling the samples are filtered through a 0.2 micro-m filter.
- The carbohydrate profile was determined by chromatography by applying standard procedures, e.g. as described in Norman,B.E. in James N.Bemiller, David J.Manners, and Robert J.Sturgeon (eds), Methods in Carbohydrate Chemistry, Volume X. John Wiley & Sons, Inc., New York, pp. 231-239, 1994.
Novamyl without substitutions was included as reference. The results were as follows:Substitutions % glucose % maltose Maltose/glucose ratio Novamyl parent 4-5 50-55 11 W93M 10 42 4.2 W93E 10 33 3.3 W93M, V230G 12 42 3.5 Y258W 8 45 5.6 Y258W, F284Y 8 22 2.8 H232M 6 22 3.7 F188T 20 51 2.6 F188G 20 44 2.2 F188V 15 55 3.7 W93G 13 52 4.0 W93V 13 36 2.8 W93T 12 37 3.1 W93S 8 36 4.5 W93T,F188V 14 27 1.9 N176L 11 50 4.5 D178V 12 51 4.3 N26S, L51M, T80A, F237L, N266Y, M330I 10 42 4.2 d(191-195)1), D261 G, T288P 8 21 2.6 W185R, D198G, E202V 16 52 3.3 T134A, H170R, D190G, V215A, F233S, I251T 4 14 3.5 G172V, D178V, G204D 11 45 4.1 R55C, K137M, 288S, S331 P, 396V 4.5 52.5 11.7 N176Y, E202D 3.5 43.1 12.3 T189M, A219V 4.1 49.8 12.1 T189M,A214T,F237L,T288S 3.2 41.6 13.1 D161G,N176Y,T189M,N203D,A214T 3.4 45.4 13.3 A148D,T189M,A219V 3.6 47.2 13.1 T189M,Q208R,A219V,D657G 4.0 50.2 12.5 F104L,N106D,K137M,D173N,N176Y,T189M, E202D,V254A,L334, P380L,G512D,Y632C 3.3 54.7 16.7 K137M,T189M,S195T,E202D,G263R,S331P, A388V,N631 S 3.7 57.8 15.5 H103R,T189M,I227V,K239R,V254A,T288S, S441P,Y460H,F649L 2.4 38.8 15.9 1) d (191-195) indicates a deletion of the amino acids corresponding to position 191, 192, 193, 194, and 195. - Further a number of variants were tested applying the same procedure as described in Example 1, except that 1.2 mg/g DS of the commercially available pullulanase Promozyme® (
EP 63909 - The following results were obtained:
Substitutions % glucose % maltose Maltose/glucose ratio Parent Novamyl 7.2 71.6 9.9 A148D,T189M,G263R,N337D,Y572C, F636L 5.9 69.8 11.9 D173N,N176Y,T189M,A219V,Y246H,T288S,L33 4P,N631S,K650R 5.5 70.6 12.8 N27S,T80I,T189M,S195T,E202D,I290V,T386A,L 596P 4.9 67.6 13.7 A148D,T189M,D212G,A219V,T288S 5.9 69.9 11.9 K137M,N158Y,N176H,T189M,E202D,V254A, S331P,A388V 5.1 63.8 12.4 - A number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase" in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000.
- Each variant was tested by incubating it with maltodextrin (DE 11) at 60°C and pH 5.5 for 42 hours as described in Example 1. Either an amount of 0.81 micro g (variants marked with [1]) or 1.62 micro g (variants marked with [2]) of the variant was added, and further 1.2 mg/g DS of the commercially available pullulanase Promozyme® (
EP 63909
Novamyl without substitutions was included as reference. The results were as follows:Substitutions % maltose % glucose Maltose/glucose ratio Novamyl parent [1] 56.7 5.5 10.3 Novamyl parent [2] 66.1 6.6 10.1 Y258W [1] 32.0 5.5 5.8 Y258W [2] 37.3 6.8 5.5 W93S [1] 40.4 11.2 3.6 W93S [2] 46.0 14.2 3.2 T189M,A214T,F237L,T288S [1] 56.6 5.0 11.3 T189M,A214T,F237L,T288S [2] 63.0 5.8 10.9 D161G,N176Y,T189M,N203D,A214T [1] 48.1 3.8 12.7 D161G,N176Y,T189M,N203D,A214T [2] 61.3 5.2 11.8 A148D,T189M,A219V [1] 54.6 4.4 12.4 A148D,T189M,A219V [2] 63.4 5.4 11.7 T189M,Q208R,A219V,D657G [1] 52.8 4.4 12.0 T189M,Q208R,A219V,D657G [2] 65.7 5.9 11.1 F104L,N106D,K137M, D173N,N176Y,T189M, E202D,V254A,L334P, P380L,G512D,Y632C [1] 35.0 2.0 17.5 F104L,N106D,K137M,D173N,N176Y,T189M, E202D,V254A,L334P,P380L,G512D, Y632C [2] 40.6 2.3 17.7 K137M,T189M,S195T,E202D,G263R,S331 P, A388V,N631S [1] 59.9 3.8 15.8 K137M,T189M,S195T,E202D,G263R,S331P, A388V,N631S [2] 67.9 4.6 14.8 H103R,T189M,1227V,K239R,V254A,T288S, S441P,Y460H,F649L [1] 36.7 2.5 15.0 H103R,T189M,1227V,K239R,V254A,T288S, S441 P,Y460H,F649L [2] 68.2 4.8 14.2 - A number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase" in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000.
- Each variant was tested by incubating it with maltodextrin (DE 11) at 60°C and pH 5.5 for 42 hours as described in Example 1. An amount 1.62 micro g (variants marked with [2]) of the variant was added.
- A single variant was dosed at a higher amount, namely 38.2 micro g (variant marked with [3]).
Substitutions % maltose % glucose Maltose/glucose ratio Parent Novamyl [2] 57.8 5.2 11.0 F188G [3] 46.2 26.3 1.8 T189M,A214T,F237L,T288S [2] 53.4 4.4 12.1 D161G,N176Y,T189M, N203D, A214T [2] 57.7 4.7 12.3 A148D,T189M,A219V [2] 56.4 4.4 12.7 T189M,Q208R,A219V, D657G [2] 55.5 4.5 12.3 - A number of purified variants (each having the sequence of SEQ ID NO: 1 with the indicated substitutions) were prepared by standard purification techniques, see e.g. Beier et al.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase" in Protein Engineering, vol. 13 no. 7 pp. 509-513, 2000.
- Each variant was tested by incubating it with amylopectin (waxy maize starch) by application of the following procedure:
- Prepare a 5% (w/w) amylopectin solution in 50mM Na-acetate, 1mM CaCl2, pH 5.5. The solution is boiled for 2 minutes or until it is dissolved.
- 1mL substrate is added to 1.5 mL tubes with lid and membrane, and samples are preheated to 60°C on a thermomixer.
- Enzyme is dosed at a dose corresponding to the amylase activity of 0.81 micro g Novamyl measured by the Phadesbas amylase assay (which is 0.045 PSU/mL substrate, when Novamyl activity is 56.8PSU/mg)
- Samples are incubated for1 hour or 24 hours at 60°C.
- 1ml Milli-Q is added with 1-2 drops of 1M HCl (pH must be less than 3 to inactive the amylase).
- Make a small hole in the lid with e.g. a needle.
- Samples are boiled for 15 minutes.
- After cooling the samples are filtered through a 0.2 micro m filter.
- The carbohydrate profile was determined by chromatography by applying standard procedures, e.g. as described in Norman,B.E. in James N.Bemiller, David J.Manners, and Robert J.Sturgeon (eds), Methods in Carbohydrate Chemistry, Volume X. John Wiley & Sons, Inc., New York, pp. 231-239, 1994.
Novamyl without substitutions was included as reference. The results were as follows:Substitutions % maltose % glucose Maltose/glucose ratio Novamyl parent [1] 53.2 1.5 35.1 Novamyl parent [24] 64.3 2.6 24.7 Y258W [1] 39.1 2.7 14.4 Y258W [24] 57.6 4.1 13.9 F188G [1] 12.3 0.0 - F188G [24] 17.4 2.4 7.2 W93S [1] 13.3 1.8 7.5 W93S [24] 52.7 15.3 3.4 F104L,N106D,K137M,D173N, N176Y,T189M,E202D,V254A, L334P,P380L,G512D,Y632C [1] 49.9 1.2 41.6 F104L,N106D,K137M,D173N, N 176Y,T189M,E202D,V254A, L334P,P380L,G512D,Y632C [24] 66.9 1.5 44.6 K137M,T189M,S195T,E202D, G263R,S331P,A388V,N631S [1] 66.2 0.6 110 K137M,T189M,S195T,E202D, G263R,S331 P,A388V,N631 S [24] 64.4 0.8 80.5 H103R,T189M,1227V,K239R, V254A,T288S,S441P,Y460H, F649L [1] 54.0 0.9 60.0 H103R,T189M,1227V,K239R, V254A,T288S,S441 P,Y460H, F649L [24] 63.0 1.3 48.5 - Two variants were tested for baking, namely Y258W and W93S. Bread was made by the European Straight Dough method with and without addition of enzymes. The texture was evaluated using standard AACC procedures, and the following results were obtained after 7 days storage:
Firmness (g) Reference: no enzyme Y258W W93S 1600 1250 1250 Elasticity % (g/g) Reference: no enzyme Y258W W93S 50 53 54 Free water mobility (micro S) Reference: no enzyme Y258W W93S 10600 10850 11100 Y258W was dosed 5 mg enzyme protein/kg flour for all three tests.
W93S was dosed 3 mg enzyme protein/kg flour for all three tests.
Claims (8)
- A polypeptide whicha) has an amino acid sequence having more than 80% identity to SEQ ID NO: 1,b) compared to SEQ ID NO: 1 has a different amino acid residue at a position corresponding to W93, T134, G172, N176, D178, F188, D190, D198, I227, V230, K231, H232, F233, Y258, G259, D260, D261, P262, T264, N266, F284, T288 or M330 or a deletion corresponding to 191-195, andc) has the ability to hydrolyze starch to form a product having a modified maltose-to-glucose ratio than a product made with the polypeptide of SEQ ID NO: 1.
- The polypeptide of the preceding claim, which compared to SEQ ID NO: 1 comprises a substitution corresponding to W93E/G/M/V/T/S, T134A, G172V, D178L/M/T/V, F188G/T/V, D190G, D198G, I227V, V230G, K231 R/L/M, 232Y/L/M, F233S, Y258W/L/M/T/V, G259A/H/Y, D260L/M/T/V, D261 G, T264Y/Q/F/A/V, N266Y, F284Y, T288Y/Q/F/A/V/P or M330I.
- The polypeptide of claim 2 or 3, which has the amino acid sequence of SEQ ID NO: 1 with the following alterations:
W93M W93E W93M, V230G Y258W Y258W, F284Y H232M F188T F188G F188V W93G W93V W93T W93S N176L D178V F188G, W93M F188G, W93E F188G, W93S F188G, W93T F188V, W93M F188V, W93E F188V, W93S F188V, W93T - A polynucleotide encoding the polypeptide of any preceding claim.
- A process for the production of ethanol, comprising treating granular starch with the polypeptide of any preceding claim and fermentation into ethanol.
- A dough comprising the polypeptide of any preceding claim.
- A method of producing dough or a baked product from dough, comprising adding the polypeptide of any preceding claim.
- A process for the production of maltose syrup comprising treating liquefied starch with the polypeptide of any preceding claim.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401173 | 2004-08-02 | ||
EP05762147A EP1797179A1 (en) | 2004-08-02 | 2005-07-22 | Maltogenic alpha-amylase variants |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05762147.6 Division | 2005-07-22 | ||
EP05762147A Division EP1797179A1 (en) | 2004-08-02 | 2005-07-22 | Maltogenic alpha-amylase variants |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2151494A2 true EP2151494A2 (en) | 2010-02-10 |
EP2151494A3 EP2151494A3 (en) | 2011-04-13 |
Family
ID=34956086
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09173277A Withdrawn EP2151494A3 (en) | 2004-08-02 | 2005-07-22 | Maltogenic alpha-amylase variants |
EP05762147A Withdrawn EP1797179A1 (en) | 2004-08-02 | 2005-07-22 | Maltogenic alpha-amylase variants |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05762147A Withdrawn EP1797179A1 (en) | 2004-08-02 | 2005-07-22 | Maltogenic alpha-amylase variants |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080032024A1 (en) |
EP (2) | EP2151494A3 (en) |
AU (1) | AU2005269079A1 (en) |
CA (1) | CA2575875A1 (en) |
WO (1) | WO2006012899A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1794291B1 (en) | 2004-09-24 | 2012-11-14 | Novozymes A/S | Method of preparing a dough-based product |
EA201591609A1 (en) | 2013-03-01 | 2016-03-31 | ДСМ АйПи АССЕТС Б.В. | ALPHA-AMILASE OPTIONS |
US9301533B2 (en) | 2013-03-01 | 2016-04-05 | Dsm Ip Assets B.V. | Alpha-amylase variants |
WO2014194034A2 (en) | 2013-05-29 | 2014-12-04 | Danisco Us Inc. | Novel metalloproteases |
EP3882346A1 (en) | 2013-05-29 | 2021-09-22 | Danisco US Inc. | Novel metalloproteases |
US20160160202A1 (en) | 2013-05-29 | 2016-06-09 | Danisco Us Inc. | Novel metalloproteases |
EP3004342B1 (en) | 2013-05-29 | 2023-01-11 | Danisco US Inc. | Novel metalloproteases |
WO2015089447A1 (en) | 2013-12-13 | 2015-06-18 | Danisco Us Inc. | Serine proteases of the bacillus gibsonii-clade |
ES2723948T3 (en) | 2013-12-13 | 2019-09-04 | Danisco Us Inc | Serine proteases from Bacillus species |
WO2015095046A1 (en) | 2013-12-16 | 2015-06-25 | E. I. Du Pont De Nemours And Company | Use of poly alpha-1,3-glucan ethers as viscosity modifiers |
AU2014364772B2 (en) | 2013-12-18 | 2018-07-26 | Nutrition & Biosciences USA 4, Inc. | Cationic poly alpha-1,3-glucan ethers |
EP3105256A1 (en) | 2014-02-14 | 2016-12-21 | E. I. du Pont de Nemours and Company | Poly-alpha-1,3-1,6-glucans for viscosity modification |
ES2734726T3 (en) | 2014-03-11 | 2019-12-11 | Du Pont | Oxidized alpha-1,2-glucan poly as a detergent booster |
MX2016012044A (en) | 2014-03-21 | 2017-06-29 | Danisco Us Inc | Serine proteases of bacillus species. |
US9714403B2 (en) | 2014-06-19 | 2017-07-25 | E I Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
WO2015195777A1 (en) | 2014-06-19 | 2015-12-23 | E. I. Du Pont De Nemours And Company | Compositions containing one or more poly alpha-1,3-glucan ether compounds |
US10362107B2 (en) * | 2014-09-04 | 2019-07-23 | Liqid Inc. | Synchronization of storage transactions in clustered storage systems |
EP3207129B1 (en) | 2014-10-17 | 2019-11-20 | Danisco US Inc. | Serine proteases of bacillus species |
EP3212783B1 (en) | 2014-10-27 | 2024-06-26 | Danisco US Inc. | Serine proteases |
US20170335306A1 (en) | 2014-10-27 | 2017-11-23 | Danisco Us Inc. | Serine proteases |
EP3212662B1 (en) | 2014-10-27 | 2020-04-08 | Danisco US Inc. | Serine proteases |
WO2016069557A1 (en) | 2014-10-27 | 2016-05-06 | Danisco Us Inc. | Serine proteases of bacillus species |
EP3550017B1 (en) | 2014-10-27 | 2021-07-14 | Danisco US Inc. | Serine proteases |
CN108064306B (en) | 2014-12-23 | 2022-11-01 | 营养与生物科学美国4公司 | Enzymatically produced cellulose |
EP3872174B1 (en) | 2015-05-13 | 2023-03-01 | Danisco US Inc. | Aprl-clade protease variants and uses thereof |
DK3307427T3 (en) | 2015-06-09 | 2023-11-06 | Danisco Us Inc | OSMOTIC BURST CAPSULES |
WO2016201069A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc | Low-density enzyme-containing particles |
WO2016201040A1 (en) | 2015-06-09 | 2016-12-15 | Danisco Us Inc. | Water-triggered enzyme suspension |
WO2016205755A1 (en) | 2015-06-17 | 2016-12-22 | Danisco Us Inc. | Bacillus gibsonii-clade serine proteases |
JP7364330B2 (en) | 2015-11-05 | 2023-10-18 | ダニスコ・ユーエス・インク | Mannanase of Paenibacillus sp. and Bacillus sp. |
US20190153417A1 (en) | 2015-11-05 | 2019-05-23 | Danisco Us Inc | Paenibacillus sp. mannanases |
EP3374400B1 (en) | 2015-11-13 | 2022-04-13 | Nutrition & Biosciences USA 4, Inc. | Glucan fiber compositions for use in laundry care and fabric care |
US10876074B2 (en) | 2015-11-13 | 2020-12-29 | Dupont Industrial Biosciences Usa, Llc | Glucan fiber compositions for use in laundry care and fabric care |
US10822574B2 (en) | 2015-11-13 | 2020-11-03 | Dupont Industrial Biosciences Usa, Llc | Glucan fiber compositions for use in laundry care and fabric care |
DK3387124T3 (en) | 2015-12-09 | 2021-08-23 | William Cuevas | COMBINATORY ALFA AMYLASE VARIANTS |
US20180362946A1 (en) | 2015-12-18 | 2018-12-20 | Danisco Us Inc. | Polypeptides with endoglucanase activity and uses thereof |
BR112018072530A2 (en) | 2016-05-03 | 2019-03-26 | Danisco Us Inc | protease variants and uses thereof |
CN109072213A (en) | 2016-05-05 | 2018-12-21 | 丹尼斯科美国公司 | Ease variants and application thereof |
EP3464599A1 (en) | 2016-05-31 | 2019-04-10 | Danisco US Inc. | Protease variants and uses thereof |
EP3472313B1 (en) | 2016-06-17 | 2022-08-31 | Danisco US Inc. | Protease variants and uses thereof |
EP3535365A2 (en) | 2016-11-07 | 2019-09-11 | Danisco US Inc. | Laundry detergent composition |
CN110312795B (en) | 2016-12-21 | 2024-07-23 | 丹尼斯科美国公司 | Protease variants and uses thereof |
EP3559226B1 (en) | 2016-12-21 | 2023-01-04 | Danisco US Inc. | Bacillus gibsonii-clade serine proteases |
CN110621778A (en) | 2017-03-15 | 2019-12-27 | 丹尼斯科美国公司 | Trypsin-like serine protease and uses thereof |
EP3601515A1 (en) | 2017-03-31 | 2020-02-05 | Danisco US Inc. | Delayed release enzyme formulations for bleach-containing detergents |
JP2020527339A (en) | 2017-06-30 | 2020-09-10 | ダニスコ・ユーエス・インク | Low-aggregation enzyme-containing particles |
CN111373039A (en) | 2017-11-29 | 2020-07-03 | 丹尼斯科美国公司 | Subtilisin variants having improved stability |
MX2020006518A (en) | 2017-12-21 | 2020-10-28 | Danisco Us Inc | Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant. |
EP3749107A1 (en) | 2018-02-08 | 2020-12-16 | Danisco US Inc. | Thermally-resistant wax matrix particles for enzyme encapsulation |
BR112020020252A2 (en) * | 2018-04-05 | 2021-01-19 | Dsm Ip Assets B.V. | MALTOGENIC ALPHA-AMYLASE VARIANT |
EP3810767A1 (en) | 2018-06-19 | 2021-04-28 | Danisco US Inc. | Subtilisin variants |
US20210363470A1 (en) | 2018-06-19 | 2021-11-25 | Danisco Us Inc | Subtilisin variants |
US20210189295A1 (en) | 2018-08-30 | 2021-06-24 | Danisco Us Inc | Enzyme-containing granules |
US20220033737A1 (en) | 2018-09-27 | 2022-02-03 | Danisco Us Inc | Compositions for medical instrument cleaning |
WO2020112599A1 (en) | 2018-11-28 | 2020-06-04 | Danisco Us Inc | Subtilisin variants having improved stability |
CN114174504A (en) | 2019-05-24 | 2022-03-11 | 丹尼斯科美国公司 | Subtilisin variants and methods of use |
US20220306968A1 (en) | 2019-06-06 | 2022-09-29 | Danisco Us Inc | Methods and compositions for cleaning |
WO2022047149A1 (en) | 2020-08-27 | 2022-03-03 | Danisco Us Inc | Enzymes and enzyme compositions for cleaning |
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
EP4284906A1 (en) | 2021-01-29 | 2023-12-06 | Danisco US Inc. | Compositions for cleaning and methods related thereto |
CN112921017B (en) * | 2021-04-23 | 2022-09-02 | 广西大学 | Aeromonas hydrophila maltose alpha-amylase mutant and application thereof |
WO2023278297A1 (en) | 2021-06-30 | 2023-01-05 | Danisco Us Inc | Variant lipases and uses thereof |
EP4396320A2 (en) | 2021-09-03 | 2024-07-10 | Danisco US Inc. | Laundry compositions for cleaning |
WO2023039270A2 (en) | 2021-09-13 | 2023-03-16 | Danisco Us Inc. | Bioactive-containing granules |
WO2023114936A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2023114939A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Subtilisin variants and methods of use |
EP4448750A2 (en) | 2021-12-16 | 2024-10-23 | Danisco US Inc. | Subtilisin variants and uses thereof |
WO2023168234A1 (en) | 2022-03-01 | 2023-09-07 | Danisco Us Inc. | Enzymes and enzyme compositions for cleaning |
WO2023250301A1 (en) | 2022-06-21 | 2023-12-28 | Danisco Us Inc. | Methods and compositions for cleaning comprising a polypeptide having thermolysin activity |
WO2024050343A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Subtilisin variants and methods related thereto |
WO2024050339A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Mannanase variants and methods of use |
WO2024050346A1 (en) | 2022-09-02 | 2024-03-07 | Danisco Us Inc. | Detergent compositions and methods related thereto |
WO2024102698A1 (en) | 2022-11-09 | 2024-05-16 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2024163584A1 (en) | 2023-02-01 | 2024-08-08 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2024186819A1 (en) | 2023-03-06 | 2024-09-12 | Danisco Us Inc. | Subtilisin variants and methods of use |
WO2024191711A1 (en) | 2023-03-16 | 2024-09-19 | Nutrition & Biosciences USA 4, Inc. | Brevibacillus fermentate extracts for cleaning and malodor control and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0063909A1 (en) | 1981-04-20 | 1982-11-03 | Novo Nordisk A/S | Debranching enzyme product, preparation and use thereof |
EP0120693B1 (en) | 1983-03-25 | 1989-05-31 | Novo Nordisk A/S | Maltogenic amylase enzyme product, preparation and use thereof |
WO1991004669A1 (en) | 1989-09-27 | 1991-04-18 | Novo Nordisk A/S | Antistaling process and agent |
WO1996023874A1 (en) | 1995-02-03 | 1996-08-08 | Novo Nordisk A/S | A method of designing alpha-amylase mutants with predetermined properties |
WO1999043794A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Maltogenic alpha-amylase variants |
WO2003068976A2 (en) | 2002-02-14 | 2003-08-21 | Novozymes A/S | Process for producing starch hydrolysate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016349A1 (en) * | 1999-09-01 | 2001-03-08 | Novozymes A/S | Method for production of maltose and/or enzymatically modified starch |
-
2005
- 2005-07-22 AU AU2005269079A patent/AU2005269079A1/en not_active Abandoned
- 2005-07-22 WO PCT/DK2005/000506 patent/WO2006012899A1/en active Application Filing
- 2005-07-22 CA CA002575875A patent/CA2575875A1/en not_active Abandoned
- 2005-07-22 EP EP09173277A patent/EP2151494A3/en not_active Withdrawn
- 2005-07-22 EP EP05762147A patent/EP1797179A1/en not_active Withdrawn
- 2005-07-22 US US11/572,272 patent/US20080032024A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0063909A1 (en) | 1981-04-20 | 1982-11-03 | Novo Nordisk A/S | Debranching enzyme product, preparation and use thereof |
EP0120693B1 (en) | 1983-03-25 | 1989-05-31 | Novo Nordisk A/S | Maltogenic amylase enzyme product, preparation and use thereof |
WO1991004669A1 (en) | 1989-09-27 | 1991-04-18 | Novo Nordisk A/S | Antistaling process and agent |
WO1996023874A1 (en) | 1995-02-03 | 1996-08-08 | Novo Nordisk A/S | A method of designing alpha-amylase mutants with predetermined properties |
WO1999043794A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Maltogenic alpha-amylase variants |
US6162628A (en) | 1998-02-27 | 2000-12-19 | Novo Nordisk A/S | Maltogenic alpha-amylase variants |
WO2003068976A2 (en) | 2002-02-14 | 2003-08-21 | Novozymes A/S | Process for producing starch hydrolysate |
Non-Patent Citations (6)
Title |
---|
BEIER ET AL.: "Conversion of the maltogenic alpha-amylase Novamyl into a CGTase", PROTEIN ENGINEERING, vol. 13, no. 7, 2000, pages 509 - 513 |
J. GREER, PROTEINS: STRUCTURE, FUNCTION AND GENETICS, vol. 7, 1990, pages 317 - 334 |
NORMAN,B.E.: "Methods in Carbohydrate Chemistry", vol. X, 1994, JOHN WILEY & SONS, INC., pages: 231 - 239 |
T.L. BLUNDELL ET AL., NATURE, vol. 326, 26 March 1987 (1987-03-26), pages 347 FF |
W. R. PEARSON: "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", METHODS IN ENZYMOLOGY, vol. 183, 1990, pages 63 - 98 |
W. R. PEARSON; D. J. LIPMAN: "Improved Tools for Biological Sequence Analysis", PNAS, vol. 85, 1988, pages 2444 - 2448 |
Also Published As
Publication number | Publication date |
---|---|
WO2006012899A1 (en) | 2006-02-09 |
US20080032024A1 (en) | 2008-02-07 |
EP1797179A1 (en) | 2007-06-20 |
EP2151494A3 (en) | 2011-04-13 |
AU2005269079A1 (en) | 2006-02-09 |
CA2575875A1 (en) | 2006-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2151494A2 (en) | Maltogenic alpha-amylase variants | |
Pan et al. | Maltooligosaccharide-forming amylase: Characteristics, preparation, and application | |
Yamamoto et al. | Crystal structures of isomaltase from Saccharomyces cerevisiae and in complex with its competitive inhibitor maltose | |
EP0536270B1 (en) | Enzymatic hydrolysis of starch to glucose, using a genetically engineered enzyme | |
Alvaro-Benito et al. | Characterization of a β-fructofuranosidase from Schwanniomyces occidentalis with transfructosylating activity yielding the prebiotic 6-kestose | |
Ramasubbu et al. | Probing the role of a mobile loop in substrate binding and enzyme activity of human salivary amylase | |
Okuyama et al. | α-Glucosidases and α-1, 4-glucan lyases: structures, functions, and physiological actions | |
CN104531636B (en) | Mutant of maltogenic amylase and preparation method of mutant | |
JP2019115361A (en) | Novel use of maltotriosyl transferase | |
US20080138864A1 (en) | Starch Process | |
JP2012511930A (en) | Hybrid alpha-amylase | |
KR20120019391A (en) | Production of isomaltooligosaccharides and uses therefor | |
EP2554666A1 (en) | A process of obtaining ethanol without glucoamylase using pseudomonas saccharophila G4-amylase and variants thereof | |
Zhao et al. | Synthesis of isomalto-oligosaccharides by Pichia pastoris displaying the Aspergillus niger α-glucosidase | |
Bláhová et al. | Maltooligosaccharides: properties, production and applications | |
US7211422B2 (en) | Polypeptide having α-isomaltosylglucosaccharide synthase activity | |
Kimura et al. | Maltotetraose, a new saccharide of tertiary property | |
CN109486791A (en) | A kind of preparation and its application of maltogenic amylase enzyme mutant | |
Saha et al. | Improved method for preparing high maltose conversion syrups | |
KR100699431B1 (en) | Brewing method with maltogenic amylase | |
US4814267A (en) | Method for preparing high conversion syrups and other sweeteners | |
US11913053B2 (en) | Application of trehalase in fermentative production | |
CN111118068B (en) | Application of alpha-glucosidase in fermentation production | |
CN108368492A (en) | Including using the composition and method of acetyl Exiguobacterium sp and bacillus coagulans alpha-glucans transferase | |
Carvalho et al. | Purification and Characterization of the α-glucosidase Produced by Thermophilic Fungus Thermoascus aurantiacus CBMAI 756 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1797179 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111014 |